Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) Shares Outstanding (Diluted Average) (2020 - 2025)

Sutro Biopharma (STRO) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 9.84% to $8.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.5 million through Dec 2025, up 9.84% year-over-year, with the annual reading at $8.5 million for FY2025, 9.84% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $8.5 million in Q4 2025 for Sutro Biopharma, down from $84.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $84.2 million in Q3 2025 to a low of $7.7 million in Q4 2024.
  • Historically, Shares Outstanding (Diluted Average) has averaged $55.0 million across 5 years, with a median of $58.7 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 41.58% in 2021 and later tumbled 87.14% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $46.1 million in 2021, then grew by 10.02% to $50.7 million in 2022, then increased by 18.57% to $60.2 million in 2023, then crashed by 87.14% to $7.7 million in 2024, then grew by 9.84% to $8.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for STRO at $8.5 million in Q4 2025, $84.2 million in Q3 2025, and $83.8 million in Q2 2025.